References
- Parker DM, Pisani P, Ferlay J. Estimates of the world-wide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 827–41.
- Cunningham D. Mature results from three large con-trolled studies with raltitrexed (Tomudex'). Br J Cancer 1998; 77 (Suppl 2): 15–21.
- Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 709–715.
- Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorec-tal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998; 16: 2739–2744.
- Vanhoefer U, Harstrick A, Kohne CH, et al. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 1999; 17: 907–913.
- Glimelius B, Hoffman K, Olafsdottir M, Pahlman L, Sjoden PO, Wennberg A. Quality of life during cytostatic ther-apy for advanced symptomatic colorectal carcinoma: a ran-domized comparison of two regimens. Eur J Cancer Clin Oncol 1989; 25: 829–835.
- Cunningham D, Zalcberg JR, Rath U. Final results of a randomised trial comparing Tomudex (raltitrexed) with 5-fluo-rouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996; 7: 961–965.
- Cocconi G, Cunningham D, VanCutsem E. Open ran-domised multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal can-cer. J Clin Oncol 1998; 16: 2943–2952.
- Aaronson NK, Ahmedzai S, Bergman B, et al. A quality of life instrument for use in international clinical trials in oncol-ogy. J Natl Cancer Inst 1993; 85: 365–376.
- Tegisen HM. Felleskatalog 2001. 43rd edition, Felleskatalogen AS Oslo, 2001.
- The tariff of public out-patient treatment valid from January 15th 2001. Oslo: The National Health Administration, 2001.
- National Health Administration. The DRG price list for 2001 and the code guide. National Health Administration, Oslo, 2001.
- Groener MGH, van Inevald BM, Byttebier G, van Hout BA, Rutten FFH. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced col-orectal cancer. Anti-Cancer Drugs 1999; 10: 283–288.
- Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163–168.
- Osterlund P, Elomaa I, Alaluhtala T, Orpana A, Joensuu H. A syndrome (SDR) characterised by fatigue, fever and flu-like (FFF) symptoms associated with raltitrexed (R) ther-apy. Proc Am Soc Clin Oncol 1999; 18: 296a (abs 1135).
- Lichinitser M, Dobrova N, Semenov N. Tomudex T and Tomudex + 5-fluorouracil (T+FU) for advanced colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: 291a (abs 1117).
- Wils J. The establishment of a large collaborative trial programme in the adjuvant treatment of colon cancer. Br J Cancer 1998; 77 (Suppl 2): 23–28.
- Maughan T, James R, Kerr D et al. Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimens in palliative chemotherapy of advanced colorectal cancer (CRC): Final results of MRC CR06. Ann Oncol 2000; 11 (Suppl.4): 43 (abs 1850).
- Sculpher M, Palmer MK, Heyes A. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. Pharmacoeconomics 2000; 17: 361–370.